Rheumatoid arthritis

Sequential treatment strategies following methotrexate inadequate response in rheumatoid arthritis: a real-world retrospective cohort study

Clin Exp RheumatolPublished Retrospective cohort study

Authors' conclusion

While b/tsDMARDs demonstrated superior efficacy and tolerability, approximately one-third of patients achieved remission through MTX dose optimisation, possibly reflecting suboptimal initial dosing. Importantly, prior csDMARD optimisation did not compromise subsequent b/tsDMARD responsiveness.

Study context

Population
Rheumatoid arthritis (RA) patients with inadequate response to initial methotrexate (MTX), from health records
Participants
45 / 194 / 37 / 57
Exposure
Direct switch to b/tsDMARD vs MTX dose escalation after MTX inadequate response; in dose-escalation non-responders, leflunomide (LEF) vs b/tsDMARD
  • Direct b/tsDMARDn = 45
  • MTX dose escalationn = 194reference
  • LEFn = 37
  • b/tsDMARD post-dose escalationn = 57
Outcome
3V-remission (modified EULAR Boolean criteria)
Follow-up
6-month intervals
Methodological detailsreal-world
  • Real-world

Main finding

As reported in the abstract

3V-remission

P < 0.001

Observational data: associations, not effects.

Further findings

OutcomeLEFb/tsDMARD post-dose escalationP value
3V-remission among MTX dose escalation non-respondersLEF vs b/tsDMARD post-dose escalation43.2%50.9%P = 0.469

b/tsDMARD 3V-remission by prior treatment exposure

After initial MTX
62.2%
Post-dose escalation
50.9%
Post-LEF
46.1%
Overall comparison
P = 0.417

Safety

OutcomeLEFb/tsDMARD post-dose escalation
Discontinuation among MTX dose escalation non-responders21.6%1.8%

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Sequential treatment strategies following methotrexate inadequate response in rheumatoid arthritis: a real-world retrospective cohort study. Clin Exp Rheumatol. Published 26 January 2026. doi:10.55563/clinexprheumatol/zssu99

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.